Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cellectar Biosciences, Inc. Director's Dealing 2015

Dec 29, 2015

35021_dirs_2015-12-29_7810cedc-cc33-448f-8384-485fcf5bb0e6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2015-12-24

Reporting Person: AWM Investment Company, Inc. (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-12-24 Common Stock S 216991 $0.7596 Disposed 333822 Indirect
2015-12-28 Common Stock S 150975 $0.6903 Disposed 182847 Indirect

Footnotes

F1: This is a weighted average price.

F2: AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Fund III QP, L.P. (SSFQP), Special Situations Cayman Fund, L.P. (CAYMAN) and Special Situations Life Sciences Fund, L.P. (SSLS and together with SSFQP and CAYMAN, the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 86,346 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 28,766 Shares held by CAYMAN and 67,735 Shares held by SSLS.

F3: Austin W. Marxe (Marxe), David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are the controlling principals of AWM.
The reporting person disclaims beneficial ownership of the Shares, except to the extent of its pecuniary interest therein. This report shall not
be deemed an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of Section 16 of the
Securities Exchange Act of 1934, as amended, or for any other purpose.